BioNTech SE Beat Consensus Estimates
Monday, May 5, 2025 at 6:45 AM ET
BioNTech SE (BNTX) reported a loss of $1.82 per share on revenue of $192.30 million for the first quarter ended March 2025. The consensus estimate was a loss of $2.77 per share on revenue of $170.69 million. The company beat consensus estimates by 34.30% while revenue fell 5.59% compared to the same quarter a year ago.
The company said it continues to expect 2025 revenue of $1.93 billion to $2.50 billion. The current consensus revenue estimate is $2.20 billion for the year ending December 31, 2025.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-1.82
Earnings Whisper®
-
Consensus Estimate
$-2.77
Earnings Surprise
Earnings Growth
Reported Revenue
$192.30 Mil
Revenue Estimate
$170.69 Mil
Revenue Surprise
Revenue Growth